EUVIMEDEUVIMED entdecken
Crossref

Rational Discovery of BACE1‐Selective Inhibitors as Potential Therapeutics for Alzheimer's Disease

Tanmaykumar Varma iD, Pradnya Kamble iD, Prabha Garg iD

Drug Development Research · 2025

DOI: 10.1002/ddr.70169 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von Tanmaykumar Varma und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacoinformatics, National Institute of Pharmaceutical Education and Research, S.A.S. Nagar, Punjab, India. Hauptthemen laut MEDLINE: Amyloid Precursor Protein Secretases, Alzheimer Disease, Aspartic Acid Endopeptidases, Enzyme Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) remains a major neurodegenerative disorder with limited therapeutic medication. Despite intensive efforts, the clinical development of β‐site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors has been hindered by off‐target effects, poor brain penetration, and toxicity, which is often due to a lack of selectivity over BACE2. In this study, we conducted a comprehensive analysis of over 9,000 reported BACE1 inhibitors to identify key physicochemical properties and interaction fingerprints associated with effective binding. These criteria were used to filter a library of 1.4 million commercially available compounds, prioritizing candidates with better safety and blood‐brain barrier (BBB) permeability properties. The top‐ranked molecules were evaluated through molecular docking and molecular dynamics (MD) simulations, followed by selectivity assessments against BACE2 and additional off‐targets. Among these, two compounds, MCULE‐5138978734 and MCULE‐2333131051, exhibited strong and stable binding to BACE1 with markedly reduced affinity for BACE2, suggesting improved selectivity. This integrative in silico framework demonstrates a rational strategy for the discovery of selective BACE1 inhibitors and highlights promising lead candidates for further experimental validation in the development of AD therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Precursor Protein SecretasesAlzheimer DiseaseAspartic Acid EndopeptidasesEnzyme InhibitorsHumansMolecular Docking SimulationDrug DiscoveryMolecular Dynamics SimulationBlood-Brain Barrier

Stichwörter der Autor:innen

Alzheimer's DiseaseBACE1Free Energy LandscapeMD simulationprincipal component analysis

Substanzen

Amyloid Precursor Protein SecretasesAspartic Acid EndopeptidasesBACE1 protein, humanBACE2 protein, humanEnzyme Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacoinformatics, National Institute of Pharmaceutical Education and Research, S.A.S. Nagar, Punjab, India.

ORCID-Profile: Tanmaykumar Varma, Pradnya Kamble, Prabha Garg

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Varma, T., Kamble, P., & Garg, P. (2025). Rational Discovery of BACE1‐Selective Inhibitors as Potential Therapeutics for Alzheimer's Disease. Drug Development Research. https://doi.org/10.1002/ddr.70169

Vancouver

Varma T, Kamble P, Garg P. Rational Discovery of BACE1‐Selective Inhibitors as Potential Therapeutics for Alzheimer's Disease. Drug Development Research. 2025. doi:10.1002/ddr.70169

BibTeX
@article{Varma2025,
  author = {Varma, Tanmaykumar and Kamble, Pradnya and Garg, Prabha},
  title = {Rational Discovery of BACE1‐Selective Inhibitors as Potential Therapeutics for Alzheimer's Disease},
  journal = {Drug Development Research},
  year = {2025},
  doi = {10.1002/ddr.70169}
}
Kostenlos starten →